Operating Lease, Right-of-Use Asset of Adverum Biotechnologies, Inc. from 31 Mar 2019 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's right to use underlying asset under operating lease.
Summary
Adverum Biotechnologies, Inc. quarterly Operating Lease, Right-of-Use Asset in USD history and change rate from 31 Mar 2019 to 30 Sep 2025.
  • Adverum Biotechnologies, Inc. Operating Lease, Right-of-Use Asset for the quarter ending 30 Sep 2025 was $29,031,000, a 14% decline year-over-year.
Source SEC data
View on sec.gov
Operating Lease, Right-of-Use Asset, Quarterly (USD)
Operating Lease, Right-of-Use Asset, YoY Quarterly Change (%)

Adverum Biotechnologies, Inc. Quarterly Operating Lease, Right-of-Use Asset (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $29,031,000 -$4,649,000 -14% 30 Sep 2025 10-Q 12 Nov 2025 2025 Q3
Q2 2025 $33,529,000 -$467,000 -1.4% 30 Jun 2025 10-Q 12 Aug 2025 2025 Q2
Q1 2025 $33,584,000 -$894,000 -2.6% 31 Mar 2025 10-Q 14 May 2025 2025 Q1
Q4 2024 $33,611,000 -$1,413,000 -4% 31 Dec 2024 10-Q 12 Nov 2025 2025 Q3
Q3 2024 $33,680,000 -$1,919,000 -5.4% 30 Sep 2024 10-K 15 Apr 2025 2024 FY
Q2 2024 $33,996,000 -$7,237,000 -18% 30 Jun 2024 10-K 15 Apr 2025 2024 FY
Q1 2024 $34,478,000 -$12,120,000 -26% 31 Mar 2024 10-K 15 Apr 2025 2024 FY
Q4 2023 $35,024,000 -$43,910,000 -56% 31 Dec 2023 10-K 15 Apr 2025 2024 FY
Q3 2023 $35,599,000 -$44,283,000 -55% 30 Sep 2023 10-K 15 Apr 2025 2024 FY
Q2 2023 $41,233,000 -$42,533,000 -51% 30 Jun 2023 10-K 15 Apr 2025 2024 FY
Q1 2023 $46,598,000 -$38,276,000 -45% 31 Mar 2023 10-K 15 Apr 2025 2024 FY
Q4 2022 $78,934,000 -$7,066,000 -8.2% 31 Dec 2022 10-K 18 Mar 2024 2023 FY
Q3 2022 $79,882,000 -$20,292,000 -20% 30 Sep 2022 10-Q 10 Nov 2022 2022 Q3
Q2 2022 $83,766,000 -$18,110,000 -18% 30 Jun 2022 10-Q 11 Aug 2022 2022 Q2
Q1 2022 $84,874,000 +$65,830,000 +346% 31 Mar 2022 10-Q 12 May 2022 2022 Q1
Q4 2021 $86,000,000 +$66,624,000 +344% 31 Dec 2021 10-K 30 Mar 2023 2022 FY
Q3 2021 $100,174,000 +$80,476,000 +409% 30 Sep 2021 10-Q 04 Nov 2021 2021 Q3
Q2 2021 $101,876,000 +$81,865,000 +409% 30 Jun 2021 10-Q 05 Aug 2021 2021 Q2
Q1 2021 $19,044,000 -$1,362,000 -6.7% 31 Mar 2021 10-Q 06 May 2021 2021 Q1
Q4 2020 $19,376,000 -$1,587,000 -7.6% 31 Dec 2020 10-K 29 Mar 2022 2021 FY
Q3 2020 $19,698,000 -$1,813,000 -8.4% 30 Sep 2020 10-Q 05 Nov 2020 2020 Q3
Q2 2020 $20,011,000 -$2,042,000 -9.3% 30 Jun 2020 10-Q 10 Aug 2020 2020 Q2
Q1 2020 $20,406,000 -$2,186,000 -9.7% 31 Mar 2020 10-Q 28 May 2020 2020 Q1
Q4 2019 $20,963,000 31 Dec 2019 10-K 01 Mar 2021 2020 FY
Q3 2019 $21,511,000 30 Sep 2019 10-Q 07 Nov 2019 2019 Q3
Q2 2019 $22,053,000 30 Jun 2019 10-Q 08 Aug 2019 2019 Q2
Q1 2019 $22,592,000 31 Mar 2019 10-Q 08 May 2019 2019 Q1
* An asterisk sign (*) next to the value indicates that the value is likely invalid.